Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients

Facility Enters Qualification to Support Late?Stage Pivotal Manufacturing and Commercial Readiness SAN DIEGO, Jan. 8, 2026 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical?stage biotechnology company pioneering autologous regenerative therapies, today announced completion of Cohort…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks